Welcome to our dedicated page for Ehave SEC filings (Ticker: EHVVF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ehave's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ehave's regulatory disclosures and financial reporting.
Ehave, Inc. filed an amended annual report for 2025 showing a tiny revenue base and significant ongoing losses while pivoting into AI-enabled software. For the year ended December 31, 2025, the company reported revenues from continuing operations of $2,183 and a net loss of $3,756,479, widening its accumulated deficit to $40,767,900.
Total assets were $3,701,771 against a shareholders’ deficit of $9,446,683, and 1,482,014,555 common shares were outstanding as of December 31, 2025. Auditors included a going concern explanatory paragraph as the company expects continued losses and notes it may not have sufficient resources to fund operations through the fourth quarter of 2026 without new capital. Management highlights a transition from digital therapeutics, including its MegaTeam ADHD platform, toward a broader AI-native technology strategy featuring AI Headhunter and early-stage AI BioLab and AI HealthOps, none of which are yet generating revenue. As of this report, Ehave has one full-time employee and relies heavily on contractors, while warning of material weaknesses in internal controls and extensive business and financing risks.
Ehave, Inc., an Ontario-based digital therapeutics and ketamine-services company, reports minimal 2025 revenue of $2,183 from continuing operations and a net loss of $3,756,479. As of December 31, 2025, the company had total assets of $3,701,771, a shareholders’ deficit of $9,446,683 and an accumulated deficit of $40,767,900, prompting its auditors to raise substantial doubt about its ability to continue as a going concern.
The share count is highly expanded, with 1,482,014,555 common shares outstanding and 1,316,810,694 weighted average shares in 2025, reflecting over 1.1 billion new shares issued that year. Ehave highlights multiple business risks, including limited operating history, continued expected losses, dependence on raising additional capital, material weaknesses in internal control over financial reporting, thin and volatile trading on the Pink Open Market, and exposure to stringent healthcare, privacy and potential FDA medical device regulations.